Farber Cancer Institute have developed a scalable platform for discovering molecular glue degraders, reporting the first ...

A preclinical study published in ACS Omega describes how AI-based molecular modelling and genetic data from Utah families were combined to identify WNK2 inhibitors as potential disease-modifying ...

A small molecule inhibitor developed at Virginia Commonwealth University has demonstrated the ability to eliminate cancer ...

What if one of gene therapy’s biggest obstacles isn’t delivery, but the body’s own cells? Discover why DNA silencing is emerging as a major challenge for long-lasting genetic medicines. Gene therapy ...

The departure of leading AI researchers from Google to found Discovery Loop raises important questions about the future ...

Dr Jonathan Cohen-Gold is Co-founder and CEO of Houdini Bio, a University of Cambridge spinout developing technology to improve the safety, durability and efficacy of cell and gene therapies. He ...

Voyager Therapeutics has presented six-month GLP toxicology data for VY1706, its investigational tau-targeting gene therapy, ...

Oblenio Bio has dosed the first patients in a Phase 1a trial of LBL-051, a tri-specific T cell engager designed to ...

Paul Michaels is a life sciences executive with more than two decades of experience building strategic partnerships and ...

A new gene therapy platform exploiting the brain's glymphatic transport system and engineered AAV5 vectors could offer a ...

Most inherited retinal diseases still have no approved therapy despite advances in gene therapy. This article explores why ...